Equitoxicity Cisplatin-RONC® and Cisplatin-Teva at a single injection to mice and rats

Introduction. The development of high-quality domestic reproduced dosage form of сisplatin is necessary to improve the treatment conditions of cancer patients. Purpose of research. Comparative preclinical study of acute toxicity of newly developed in SIC Oncology reproduced dosage form Cisplatin-RONC® with commercial preparation Cisplatin-Teva. Materials and methods. The standard methods of estimation of acute toxicity of preparations on small laboratory rodents are used. Results. Acute toxicity of the compared forms of cisplatin is not significantly different from the effect on the survival and body weight of experimental animals. Summary. Compared generic and commercial formulations cisplatin almost equitoxic after a single intravenous administration to mice and rats.